Group 1 - The core point of the article is that Yipinhong announced the approval of its subsidiary Guangzhou Lianrui Pharmaceutical Co., Ltd. for the registration of Cimetidine injection by the National Medical Products Administration [2] Group 2 - The approval signifies a regulatory milestone for the company, potentially enhancing its product portfolio in the pharmaceutical market [2] - Cimetidine is commonly used for treating conditions related to excess stomach acid, indicating a strategic focus on gastrointestinal therapies [2] - This development may lead to increased revenue opportunities for the company as it expands its offerings in the pharmaceutical sector [2]

Group 1 - The core point of the article is that Yipinhong has received a drug registration certificate for its product, Compound Polyethylene Glycol Electrolyte Powder (III), from the National Medical Products Administration [2] Group 2 - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., is the entity that received the approval [2]

Group 1 - Jiejia Weichuang expects a net profit of 1.7 billion to 1.96 billion yuan for the first half of 2025, representing a year-on-year increase of 38.65% to 59.85% [1] - Micron Biotech's CS231295 clinical trial application has been approved by the FDA for treating advanced solid tumors [1] - Sinopec anticipates a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, a decrease of 39.5% to 43.7% year-on-year [2] Group 2 - High Energy Environment has obtained a loan commitment letter from a financial institution for share repurchase [2] - Electric Power Investment Energy received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inadequate disclosure in its semi-annual report [3] - Zhejiang University Net New won a bid for an intelligent engineering project worth 94.2712 million yuan [5] Group 3 - Daodaoquan reported a net profit of 181 million yuan for the first half of 2025, a year-on-year increase of 563.15% [8] - New Light Optoelectronics expects a net loss of 19 million to 23 million yuan for the first half of 2025 [9] - Aihua Pharmaceutical's two probiotic powder registration applications have been accepted [10] Group 4 - Xinhui Electric's subsidiary signed a product sales framework contract for commercial and household robots [11] - Baida Precision Engineering's subsidiary obtained 134,500 square meters of industrial land use rights [12] - Haiyang Technology's chief engineer resigned for personal reasons [13] Group 5 - Tianhe Magnetic Materials received a project filing notice for a 12,000-ton magnetic material deep processing project [22] - Wanlima is the pre-selected unit for a procurement project worth 43.835 million yuan from China Southern Airlines [24] - Yipin Hong's subsidiaries obtained two drug registration certificates [25] Group 6 - Zhejiang Jiaoke's subsidiary signed new construction projects worth 4.783 billion yuan in the second quarter [27] - Shenglan Co. received approval for issuing convertible bonds [29] - Jimi Technology expects a net profit of 88.6622 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [31] Group 7 - Dingtong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06% [32] - Huaheng Biological is planning to list on the Hong Kong Stock Exchange [34] - Yuntian Lihui submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [36] Group 8 - Nanchip Technology expects a net profit of 108.8 million to 133.1 million yuan for the first half of 2025, a decrease of 35.09% to 47.03% year-on-year [43] - Anglikang's Mesobam injection has received a drug registration certificate [44] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.998% [45]

Group 1 - Shenglan Co., Ltd. has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds to unspecified objects [1] - Yipin Hong's wholly-owned subsidiary, Guangzhou Yipin Pharmaceutical, has obtained the registration certificate for Compound Polyethylene Glycol Electrolyte Powder (III), qualifying it to sell this specification of drug in the domestic market [1] - Zhejiang Jiaokao disclosed its second-quarter construction industry operating situation, reporting that its subsidiary, Zhejiang Jiaogong, won and signed 207 new projects in the second quarter, amounting to 4.783 billion yuan; for the first half of the year, a total of 539 new projects were won and signed, totaling 21.355 billion yuan [1] Group 2 - Weilon Co., Ltd. is approaching the final half trading day before the "Weilon Convertible Bonds" stop conversion and redemption; after the market closes on July 31, unconverted "Weilon Convertible Bonds" will cease conversion, and the remaining convertible bonds will be forcibly redeemed at a price of 100.485 yuan per bond, which may result in losses for investors [1]

此次公司获得复方聚乙二醇电解质散(Ⅲ)注册证书，标志着公司具备了在国内市场销售该规格药品的资 格，将进一步丰富公司产品管线和产品品类，增强了公司的核心竞争力。 一品红（300723）(300723.SZ)发布公告，公司全资子公司广州一品红制药有限公司于近日收到国家药 品监督管理局核准签发的关于复方聚乙二醇电解质散(Ⅲ)的《药品注册证书》，复方聚乙二醇电解质散 (Ⅲ)适应症为：用于以下情况之前的患者结肠清洁准备：--内窥镜或放射检查--结肠手术，本品适用于成 人。 ...

Core Viewpoint - The company Yipinhong (300723.SZ) has received the drug registration certificate for Compound Polyethylene Glycol Electrolyte Powder (III) from the National Medical Products Administration, allowing it to sell this product in the domestic market, which enhances its product pipeline and core competitiveness [1] Group 1 - The registration certificate is specifically for the use of the product in bowel cleansing preparation for patients prior to procedures such as endoscopy, radiological examinations, and colorectal surgery, applicable to adults [1] - This approval signifies the company's capability to market this specific drug formulation in China, thereby expanding its product offerings [1] - The introduction of this product is expected to strengthen the company's competitive edge in the pharmaceutical industry [1]

Core Viewpoint - The company has received the drug registration certificate for Cimetidine Injection from the National Medical Products Administration, allowing it to sell this product in the domestic market, which enhances its competitiveness in the chronic disease medication sector [1] Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the registration certificate for Cimetidine Injection, indicating its eligibility to market this drug in China [1] - Cimetidine Injection is indicated for the treatment of gastrointestinal ulcers, expanding the company's product pipeline and categories [1] - This approval is expected to strengthen the company's position in the chronic disease medication market [1]

Core Viewpoint - The company Yipinhong (300723.SZ) has received the drug registration certificate for Cimetidine Injection from the National Medical Products Administration, allowing it to sell this product in the domestic market, which enhances its competitiveness in the chronic disease medication sector [1]. Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the registration certificate for Cimetidine Injection, indicating its eligibility to market this drug in China [1]. - The indication for Cimetidine Injection is for the treatment of gastrointestinal ulcers, which expands the company's product offerings [1]. - This approval will further enrich the company's product pipeline and categories, strengthening its position in the chronic disease medication field [1].

证券代码：300723 证券简称：一品红 公告编号：2025-049 一品红药业集团股份有限公司 关于全资子公司获得复方聚乙二醇电解质散（Ⅲ）注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于复方聚乙二醇电 解质散（Ⅲ）的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 注册分类：化学药品 4 类 规 格：本品为复方制剂，每袋含：聚乙二醇 4000 64g，硫酸钠 5.7g， 氯化钠 1.46g，氯化钾 0.75g，碳酸氢钠 1.68g 药品注册标准编号：YBH18342025 药品有效期：24 个月 申请事项：药品注册（境内生产） 包装规格： 每盒 4 袋 处方药/非处方药：处方药 药品通用名称：复方聚乙二醇电解质散（Ⅲ） 英文名/拉丁名：Polyethylene Glycol Electrolytes Powder(Ⅲ) 主要成份：聚乙二醇 4000、硫酸钠、氯化钠、氯化钾、碳酸氢钠 剂 型：散剂 --内 ...

证券代码：300723 证券简称：一品红 公告编号：2025-050 一品红药业集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州市联瑞 制药有限公司于近日收到国家药品监督管理局核准签发的关于西咪替丁注射液 的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：西咪替丁注射液 英文名/拉丁名：Cimetidine Injection 主要成份：西咪替丁 剂 型：注射剂 注册分类：化学药品 3 类 关于全资子公司获得西咪替丁注射液注册证书的公告 规 格：2ml:0.2g 药品注册标准编号：YBH18172025 药品有效期：12 个月 申请事项：药品注册（境内生产） 包装规格： 10 支/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 上市许可持有人： ...